Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125473 · ClinicalTrials.gov registry record · Phase 1
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
A Phase 1 study, sponsored by Vaxart.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03125473 is a Phase 1 study that has completed, run by Vaxart. The registered enrollment target is 66 participants.
The verdict
NCT03125473, a Phase 1 study, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
Interventions
- BIOLOGICAL VXA-G1.1-NN Oral Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2018-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125473
The ClinicalTrials.gov registry entry for NCT03125473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VXA-G1.1-NN Oral Vaccine is the first listed.
NCT03125473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03125473 about?
NCT03125473 is a clinical study titled "Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers". A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
What is the current status of trial NCT03125473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2017-04-07. Estimated completion is 2018-05-06.
What interventions are being tested in trial NCT03125473?
The interventions under investigation include: VXA-G1.1-NN Oral Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03125473?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.